180716-18-1Relevant academic research and scientific papers
Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
-
, (2008/06/13)
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans
Mewshaw, Richard E.,Kavanagh, Joseph,Stack, Gary,Marquis, Karen L.,Shi, Xiaojie,Kagan, Michael Z.,Webb, Michael B.,Katz, Alan H.,Park, Anna,Kang, Young H.,Abou-Gharbia, Magid,Scerni, Rosemary,Wasik, Theodore,Cortes-Burgos, Luz,Spangler, Taylor,Brennan, Julie A.,Piesla, Michael,Mazandargmi, Hossein,Cockett, Mark I.,Ochalski, Rafal,Coupet, Joseph,Andree, Terrance H.
, p. 4235 - 4256 (2007/10/03)
A series of 2-(aminomethyl)chromans (2-AMCs) was synthesized and evaluated for their affinity and selectivity for both the high- and low- affinity agonist states (D2(High) and D2(Low), respectively) of the dopamine (DA) D2
